Related references
Note: Only part of the references are listed.Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose
Selvam Kasthuri et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2021)
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)
Kyu Yong Cho et al.
DIABETES OBESITY & METABOLISM (2020)
Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes
Jingyi Lu et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Positioning time in range in diabetes management
Andrew Advani
DIABETOLOGIA (2020)
Recommendations on the Proper Use of SGLT2 Inhibitors
Norio Abiru et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
Ayako Fuchigami et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Glycemic Targets: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Flash glucose monitoring in type 1 diabetes: A comparison with self-monitoring blood glucose
Naru Babaya et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease
Laura Mayeda et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes
Jee Hee Yoo et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease
Yoshimasa Aso et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino et al.
DIABETES CARE (2019)
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Roy W. Beck et al.
DIABETES CARE (2019)
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
Takayoshi Suga et al.
MOLECULAR METABOLISM (2019)
Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring
Fumi Uemura et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control
Tonya D. Riddlesworth et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes
Jingyi Lu et al.
DIABETES CARE (2018)
Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic beta-cells in people with type 2 diabetes
Chang Ho Ahn et al.
DIABETES OBESITY & METABOLISM (2018)
A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
Hiroshi Nomoto et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study
Thomas Forst et al.
DIABETES OBESITY & METABOLISM (2017)
Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes
J. Mondick et al.
DIABETES OBESITY & METABOLISM (2016)
Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy
Chiho Yamamoto et al.
ENDOCRINE JOURNAL (2016)
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study
S. Sha et al.
DIABETES OBESITY & METABOLISM (2015)
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin
Andrea Tura et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents
Takahiro Oguma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Multi-Scale Glycemic Variability: A Link to Gray Matter Atrophy and Cognitive Decline in Type 2 Diabetes
Xingran Cui et al.
PLOS ONE (2014)
Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study
Noriko Ihana et al.
DIABETOLOGY & METABOLIC SYNDROME (2014)
Increased Glycemic Variability Is Independently Associated With Length of Stay and Mortality in Noncritically Ill Hospitalized Patients
Carlos E. Mendez et al.
DIABETES CARE (2013)
Rate of Hypoglycemia in Insulin-Treated Patients with Type 2 Diabetes Can Be Predicted from Glycemic Variability Data
Yongming Qu et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Postprandial Glucose: Marker or Risk Factor?
Angelo Avogaro
DIABETES CARE (2011)
Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring
Dongyuan Xing et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
Juris J. Meier et al.
DIABETES (2010)
Capillary and Venous Blood Glucose Concentrations Measured During Intravenous Insulin and Glucose Infusion: A Comparison of Steady and Dynamic States
Kirsten Kempe et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2009)
Translating the A1C assay into estimated average glucose values
David M. Nathan et al.
DIABETES CARE (2008)
Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes
Katherine Esposito et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic Hyperglycemia in patients with type 2 diabetes
L Monnier et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin
T Nakagami
DIABETOLOGIA (2004)
Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts
Q Qiao et al.
DIABETOLOGIA (2000)
Share Paper
